Pharmaceutical formulations
AssigneeSmithKline Beecham Corporation
InventorsKenneth Coleman, Jane Elizabeth Neale
Life of this patent
Estimating the term…
Abstract
A pharmaceutical formulation comprises, in combination with a penem of formula (I): in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula: wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a β-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.
Claims6
A method of treating or preventing a bacterial infection, which method comprises separately administering to a human or animal in need of said treatment, (a) a pharmaceutical formulation comprising a penem of formula (I):
- in which:
- R1 is hydrogen or an organic substituent group;
- R2 is a fused bicyclic heterocyclic ring system of the formula:
- werein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown;
- m is 2 or 3;
- p is zero, 1 or 2;
- and R3 is hydrogen, a salt-forming cation or an ester-forming group;
- and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier;
- and (b) a pharmaceutically acceptable formulation comprising the ββ-lactam antibiotic piperacillin or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
A method of inhibiting hydrolysis by ββ-lactamase of piperacillin or a pharmaceutically acceptable derivative, in a human or animal, which method comprises separately administering to a said human or animal (a) a pharmaceutical formulation comprising a ββ-lactamase inhibitory amount of a penem of formula (I):
- wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown;
- m is 2 or 3;
- p is zero, 1 or 2;
- and R3 is hydrogen, a salt-forming cation or an ester-forming group;
- and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier;
- and (b) a pharmaceutically acceptable formulation comprising the ββ-lactam antibiotic piperacillin or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.